Mallinckrodt agreed to hand lenders control of the pharmaceutical company through its second bankruptcy filing in three years while reducing by roughly $1 billion the settlement payments it had pledged for its alleged role in the opioid crisis.
Mallinckrodt agreed to hand lenders control of the pharmaceutical company through its second bankruptcy filing in three years while reducing by roughly $1 billion the settlement payments it had pledged for its alleged role in the opioid crisis.